The one medication making Dis-Chem’s wallet fat

Dis-Chem's dispensary revenue surged 10% in the six months through August, more than double the market-value growth rate of 5.1%, as the company's Better Rewards incentive and the rapid adoption of GLP-1 medicines drove a significant increase in pharmacy sales. This unexpected boost is attributed to the success of these two initiatives, which have not only lifted the value of Dis-Chem's pharmacy sales but also had a negative impact on the company's shares, which fell as much as 12% in early trade.